Catalyst Pharmaceuticals (NASDAQ:CPRX) Rating Increased to Strong-Buy at StockNews.com

StockNews.com upgraded shares of Catalyst Pharmaceuticals (NASDAQ:CPRX) from a buy rating to a strong-buy rating in a report published on Friday.

A number of other brokerages have also weighed in on CPRX. Stephens restated an “overweight” rating and set a $33.00 price objective on shares of Catalyst Pharmaceuticals in a research note on Thursday. Baird R W raised shares of Catalyst Pharmaceuticals to a “strong-buy” rating in a research report on Monday, February 3rd. Robert W. Baird began coverage on shares of Catalyst Pharmaceuticals in a report on Tuesday, February 4th. They issued an “outperform” rating and a $28.00 price target on the stock. HC Wainwright reissued a “buy” rating and set a $35.00 price objective on shares of Catalyst Pharmaceuticals in a report on Friday. Finally, Truist Financial boosted their target price on shares of Catalyst Pharmaceuticals from $30.00 to $36.00 and gave the stock a “buy” rating in a research report on Monday, November 11th. Eight research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average price target of $32.00.

Catalyst Pharmaceuticals Price Performance

NASDAQ:CPRX opened at $22.89 on Friday. The firm has a 50-day moving average of $22.21 and a two-hundred day moving average of $21.40. The stock has a market cap of $2.73 billion, a P/E ratio of 19.40, a PEG ratio of 3.31 and a beta of 0.80. Catalyst Pharmaceuticals has a 1-year low of $14.47 and a 1-year high of $24.64.

Insider Transactions at Catalyst Pharmaceuticals

In related news, insider Steve Miller sold 50,000 shares of the stock in a transaction dated Tuesday, December 10th. The shares were sold at an average price of $21.93, for a total transaction of $1,096,500.00. Following the sale, the insider now owns 686,996 shares in the company, valued at $15,065,822.28. This represents a 6.78 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 11.00% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the stock. Creative Planning boosted its holdings in shares of Catalyst Pharmaceuticals by 26.9% during the third quarter. Creative Planning now owns 12,724 shares of the biopharmaceutical company’s stock valued at $253,000 after acquiring an additional 2,699 shares during the period. Wealth Enhancement Advisory Services LLC boosted its stake in Catalyst Pharmaceuticals by 11.0% during the 3rd quarter. Wealth Enhancement Advisory Services LLC now owns 20,017 shares of the biopharmaceutical company’s stock valued at $398,000 after purchasing an additional 1,989 shares during the period. DekaBank Deutsche Girozentrale boosted its stake in Catalyst Pharmaceuticals by 48.6% during the 3rd quarter. DekaBank Deutsche Girozentrale now owns 183,376 shares of the biopharmaceutical company’s stock valued at $3,532,000 after purchasing an additional 60,000 shares during the period. Summit Global Investments grew its position in Catalyst Pharmaceuticals by 2.6% in the 3rd quarter. Summit Global Investments now owns 77,292 shares of the biopharmaceutical company’s stock worth $1,537,000 after purchasing an additional 1,923 shares during the last quarter. Finally, CWA Asset Management Group LLC acquired a new stake in shares of Catalyst Pharmaceuticals in the third quarter valued at approximately $534,000. 79.22% of the stock is currently owned by institutional investors.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.